ArticleTherapeutic advances in gastroenterology2025

Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.

Marc Ferrante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.